Christelle Schofield1, Robert U Newton2,3, Paul A Cohen4,5,6, Daniel A Galvão2, Joanne A McVeigh7,8, Ganendra R Mohan4,5,9,10, Jason Tan4,5,9,11, Stuart G Salfinger4,5,9,12, Leon M Straker13, Carolyn J Peddle-McIntyre2. 1. Exercise Medicine Research Institute, Edith Cowan University, 270 Joondalup Drive, Joondalup, WA, 6027, Australia. cschofie@our.ecu.edu.au. 2. Exercise Medicine Research Institute, Edith Cowan University, 270 Joondalup Drive, Joondalup, WA, 6027, Australia. 3. UQ Centre for Clinical Research, University of Queensland, Herston, 4029, QLD, Australia. 4. St John of God Hospital Bendat Family Comprehensive Cancer Centre, Level 5, 12 Salvado Road, Subiaco, WA, 6008, Australia. 5. Division of Women's and Infants' Health, School of Medicine, University of Western Australia, Crawley, 6009, WA, Australia. 6. Institute for Health Research, University of Notre Dame Australia, Fremantle, 6160, WA, Australia. 7. School of Occupational Therapy and Social Work, Curtin University, Kent Street, Bentley, WA, 6102, Australia. 8. Exercise Laboratory, School of Physiology, University of Witwatersrand, Johannesburg, 2000, South Africa. 9. School of Medicine, University of Notre Dame Australia, Fremantle, 6160, WA, Australia. 10. , Hollywood Medical Centre Suite 32, Level 1 / 85 Monash Avenue, Nedlands, WA, 6009, Australia. 11. WOMEN Centre, Suite 20, 2 McCourt Street, West Leederville, WA, 6007, Australia. 12. St John of God Hospital, The Consulting Suite (H203), 12 Salvado Road, Subiaco, WA, 6008, Australia. 13. School of Physiotherapy and Exercise Science, Curtin University, Kent Street, Bentley, WA, 6102, Australia.
Abstract
PURPOSE: Little is known about the relationship between health-related quality of life (HRQoL), pelvic floor dysfunction (PFD), and modifiable lifestyle and physiological factors for ovarian cancer survivors (OCS). The primary aim of the study was to compare post-treatment advanced-stage OCS with age-matched controls on measures of HRQoL and PFD. The secondary aim was to examine associations between HRQoL, PFD, objective activity behaviors, physical function, and body composition in OCS. METHODS: Twenty advanced-stage OCS and 20 controls completed questionnaires assessing HRQoL (SF-36) and PFD (Australian Pelvic Floor Questionnaire), and underwent objective assessments of activity behavior (7-day accelerometry), physical function (400-m walk, repeated chair rise, 6-m usual-pace walk, one-repetition maximum chest press, and single-leg extension), and body composition (dual-energy x-ray absorptiometry). RESULTS: Compared to controls, OCS had worse physical HRQoL (- 4.3 median difference, p = 0.013), but equivalent self-reported PFD, indicated by combined bladder, bowel, and pelvic organ prolapse symptoms (0.89 mean difference, p = 0.277). In OCS, physical HRQoL was significantly negatively associated with PFD (r = 0.468, p = 0.043). Decreased physical HRQoL and increased PFD were significantly associated with less moderate-to-vigorous physical activity in ≥ 10-min bouts (ρ = 0.627, p = 0.003; ρ = - 0.457, p = 0.049), more sedentary time (r = - 0.449, p = 0.047; r = 0.479, p = 0.038), and slower 400-m walk time (ρ = - 0.565, p = 0.022; ρ = 0.504, p = 0.028). CONCLUSIONS: Post-treatment advanced-stage OCS have decreased physical HRQoL, which is associated with modifiable factors such as worse PFD, less moderate-to-vigorous physical activity, more sedentary time, and decreased objective physical function. This highlights the need for ongoing supportive care and multidisciplinary interventions after first-line ovarian cancer treatment.
PURPOSE: Little is known about the relationship between health-related quality of life (HRQoL), pelvic floor dysfunction (PFD), and modifiable lifestyle and physiological factors for ovarian cancer survivors (OCS). The primary aim of the study was to compare post-treatment advanced-stage OCS with age-matched controls on measures of HRQoL and PFD. The secondary aim was to examine associations between HRQoL, PFD, objective activity behaviors, physical function, and body composition in OCS. METHODS: Twenty advanced-stage OCS and 20 controls completed questionnaires assessing HRQoL (SF-36) and PFD (Australian Pelvic Floor Questionnaire), and underwent objective assessments of activity behavior (7-day accelerometry), physical function (400-m walk, repeated chair rise, 6-m usual-pace walk, one-repetition maximum chest press, and single-leg extension), and body composition (dual-energy x-ray absorptiometry). RESULTS: Compared to controls, OCS had worse physical HRQoL (- 4.3 median difference, p = 0.013), but equivalent self-reported PFD, indicated by combined bladder, bowel, and pelvic organ prolapse symptoms (0.89 mean difference, p = 0.277). In OCS, physical HRQoL was significantly negatively associated with PFD (r = 0.468, p = 0.043). Decreased physical HRQoL and increased PFD were significantly associated with less moderate-to-vigorous physical activity in ≥ 10-min bouts (ρ = 0.627, p = 0.003; ρ = - 0.457, p = 0.049), more sedentary time (r = - 0.449, p = 0.047; r = 0.479, p = 0.038), and slower 400-m walk time (ρ = - 0.565, p = 0.022; ρ = 0.504, p = 0.028). CONCLUSIONS: Post-treatment advanced-stage OCS have decreased physical HRQoL, which is associated with modifiable factors such as worse PFD, less moderate-to-vigorous physical activity, more sedentary time, and decreased objective physical function. This highlights the need for ongoing supportive care and multidisciplinary interventions after first-line ovarian cancer treatment.
Entities:
Keywords:
Health-related quality of life; Moderate-to-vigorous physical activity (MVPA); Ovarian cancer; Pelvic floor dysfunction; Sedentary time
Authors: Charles E Matthews; Kong Y Chen; Patty S Freedson; Maciej S Buchowski; Bettina M Beech; Russell R Pate; Richard P Troiano Journal: Am J Epidemiol Date: 2008-02-25 Impact factor: 4.897
Authors: Shiraz I Mishra; Roberta W Scherer; Claire Snyder; Paula M Geigle; Debra R Berlanstein; Ozlem Topaloglu Journal: Cochrane Database Syst Rev Date: 2012-08-15
Authors: A L Stewart; S Greenfield; R D Hays; K Wells; W H Rogers; S D Berry; E A McGlynn; J E Ware Journal: JAMA Date: 1989-08-18 Impact factor: 56.272
Authors: Yang Zhou; Melinda L Irwin; Leah M Ferrucci; Ruth McCorkle; Elizabeth A Ercolano; Fangyong Li; Kevin Stein; Brenda Cartmel Journal: Gynecol Oncol Date: 2016-04-19 Impact factor: 5.482
Authors: Helena C Frawley; Kuan-Yin Lin; Catherine L Granger; Rosemary Higgins; Michael Butler; Linda Denehy Journal: Support Care Cancer Date: 2019-06-27 Impact factor: 3.603